Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
ONO-1110 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
29 September 2026
ONO-1110: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
BW-1010 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
29 September 2026
BW-1010: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
CIK therapy(Beijing Biohealthcare Biotechnology) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
29 September 2026
CIK therapy(Beijing Biohealthcare Biotechnology): Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market
9 min read
HR-003 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
29 September 2026
HR-003: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
Shiwei Shufeng Granules Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
29 September 2026
Shiwei Shufeng Granules: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
Repibresib Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
29 September 2026
Repibresib: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
AT-278 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
29 September 2026
AT-278: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
Tuberculosis vaccine H56IC(Statens Serum Institute) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
29 September 2026
Tuberculosis vaccine H56IC(Statens Serum Institute): Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, mar
9 min read
Turletricin Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
29 September 2026
Turletricin: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
Jinshengyuan Capsule Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
29 September 2026
Jinshengyuan Capsule: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
HL-08 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
29 September 2026
HL-08: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
Regan Syrup Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
29 September 2026
Regan Syrup: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.